Loading...
Fluoxetine in the management of major depressive disorder in children and adolescents: A meta-analysis of randomized controlled trials
Antoun Reyad, Ayman Plaha, Kiran Girgis, Eriny Mishriky, Raafat
Antoun Reyad, Ayman
Plaha, Kiran
Girgis, Eriny
Mishriky, Raafat
Editors
Other contributors
Affiliation
Epub Date
Issue Date
2020-06-04
Submitted date
Subjects
Alternative
Abstract
Fluoxetine is a serotonin specific reuptake inhibitor anti-depressant and is the only approved pharmacological treatment for major depressive disorder (MDD) in children and adolescent. We searched the published randomized controlled-trials (RCT) to review fluoxetine efficacy and tolerability using the databases PubMed, EUDRACT, ClinicalTrials.gov and Cochrane Central Register of Controlled Trials for fluoxetine role in managing MDD in children and adolescents. A meta-analysis was conducted using the identified 7 clinical trials to assess efficacy using the outcomes: Children’s Depression Rating Scale-Revised (CDRS-R), Clinical Global Impressions – Severity of Illness (CGI-S) and Clinical Global Impressions – Improvement (CGI-I) response rate. The risk of discontinuation due to adverse effects and common side effects were examined. The mean difference in change from baseline for CDRS-R was -2.72 [95% Confidence Interval (CI) -3.96, -1.48] favouring fluoxetine treatment (p<0.001). Similarly, mean difference for CGI-S was -0.21 [95% CI -0.36, -0.06]. The risk ratio (RR) of discontinuing due to adverse events was 0.98 [95% CI 0.54, 1.83], with RR for headache side effects 1.34 [95% CI 1.03, 1.74] and rash 2.6 [95% CI 1.32, 5.14]. Fluoxetine demonstrates significant improvements in symptom intensity control in young patients suffering from MDD and is considered well-tolerated with similar rates of trials discontinuation; however, fluoxetine was associated with a higher risk of headache and rash side effects. These findings will guide psychiatrists and pharmacists in their clinical role for supporting the care of young mental health patients.
Citation
Antoun Reyad, A., Plaha, K., Girgis, E. and Mishriky, R. (2020) Fluoxetine in the management of major depressive disorder in children and adolescents: A meta-analysis of randomized controlled trials, Hospital Pharmacy DOI: 10.1177/0018578720925384
Publisher
Journal
Research Unit
PubMed ID
PubMed Central ID
Embedded videos
Additional Links
Type
Journal article
Language
en
Description
This is an accepted manuscript of an article to be published by SAGE in Hospital Pharmacy on 04/06/2020.
The accepted version of the publication may differ from the final published version.
Series/Report no.
ISSN
0018-5787